Lyell Immunopharma (LYEL) Depreciation & Amortization (CF) (2020 - 2026)

Lyell Immunopharma has reported Depreciation & Amortization (CF) for 7 years, with the latest figure at $2.3 million in Q1 2026.

• Quarterly Depreciation & Amortization (CF) fell 32.23% year-over-year to $2.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $10.4 million (down 42.21% YoY) and the FY2025 annual result came in at $11.5 million, down 41.22% from the prior year.
• Depreciation & Amortization (CF) declined to $2.3 million in Q1 2026 per LYEL's latest filing, from $2.4 million in the prior quarter.
• Over five years, Depreciation & Amortization (CF) peaked at $5.1 million in Q3 2023 and troughed at $2.3 million in Q1 2026.
• A 5-year average of $4.2 million and a median of $4.7 million in 2024 frame the typical range for Depreciation & Amortization (CF).
• The sharpest annual moves came in 2022 and 2025: Depreciation & Amortization (CF) soared 113.84% in 2022, then plunged 52.31% in 2025.
• Over 5 years, Depreciation & Amortization (CF) stood at $5.0 million in 2022, then increased by 0.32% to $5.1 million in 2023, then decreased by 0.61% to $5.0 million in 2024, then slumped by 52.31% to $2.4 million in 2025, then fell by 2.71% to $2.3 million in 2026.
• According to Business Quant data, Depreciation & Amortization (CF) over the past three periods registered $2.3 million, $2.4 million, and $2.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.